Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 9/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6410071 | 0.99 | UTS2R (0.44) | UTS2RROCK2ROCK1LIPGS1PR2 | |
| SCHEMBL6413738 | 0.91 | UTS2R (0.55) | UTS2RROCK2ROCK1WDR91HDAC6 | |
| SCHEMBL6408477 | 0.91 | UTS2R (0.52) | UTS2RROCK2ROCK1WDR91HDAC6 | |
| SCHEMBL6416471 | 0.90 | UTS2R (0.49) | UTS2RROCK2ROCK1S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL6409140 | 0.90 | UTS2R (0.55) | UTS2RROCK2ROCK1WDR91HDAC6 | |
| Hydrochloric Acid SCHEMBL6412861 | 0.90 | UTS2R (0.51) | UTS2RROCK2ROCK1WDR91HDAC6 | |
| SCHEMBL5419031 | 0.90 | ROCK2 (0.46) | UTS2RROCK2ROCK1LIPGPPARG | |
| Hydrochloric Acid SCHEMBL6409279 | 0.90 | UTS2R (0.48) | UTS2RROCK2ROCK1S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL6409268 | 0.89 | ROCK2 (0.45) | UTS2RROCK2ROCK1LIPGPPARG | |
| SCHEMBL6411091 | 0.89 | PPARG (0.45) | UTS2RROCK2ROCK1LIPGPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | UTS2R 126/4885ROCK2 1735/4885ROCK1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.